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Background: Sentinel node biopsy often results in the identification and removal of multiple nodes as sentinel
nodes, although most of these nodes could be non-sentinel nodes. This study investigated whether computed
tomography-lymphography (CT-LG) can distinguish sentinel nodes from non-sentinel nodes and whether sentinel
nodes identified by CT-LG can accurately stage the axilla in patients with breast cancer.
Methods: This study included 184 patients with breast cancer and clinically negative nodes. Contrast agent was
injected interstitially. The location of sentinel nodes was marked on the skin surface using a CT laser light navigator
system. Lymph nodes located just under the marks were first removed as sentinel nodes. Then, all dyed nodes or
all hot nodes were removed.
Results: The mean number of sentinel nodes identified by CT-LG was significantly lower than that of dyed and/or
hot nodes removed (1.1 vs 1.8, p <0.0001). Twenty-three (12.5%) patients had ≥2 sentinel nodes identified by CT-LG
removed, whereas 94 (51.1%) of patients had ≥2 dyed and/or hot nodes removed (p <0.0001). Pathological
evaluation demonstrated that 47 (25.5%) of 184 patients had metastasis to at least one node. All 47 patients
demonstrated metastases to at least one of the sentinel nodes identified by CT-LG.
Conclusions: CT-LG can distinguish sentinel nodes from non-sentinel nodes, and sentinel nodes identified by
CT-LG can accurately stage the axilla in patients with breast cancer. Successful identification of sentinel nodes using
CT-LG may facilitate image-based diagnosis of metastasis, possibly leading to the omission of sentinel node biopsy.
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Sentinel node biopsy has been established as a standard
of care in the treatment of breast cancer. This technique
represents a minimally invasive, highly accurate method
of axillary staging and is an alternative to conventional
axillary lymph node dissection [1-5]. Controversy exists
regarding the several technical and clinical aspects of
sentinel node biopsy. One of the most important issues
is how many and which axillary lymph nodes need to be
removed as sentinel nodes for accurate axillary staging.
Sentinel node biopsy using dye and/or radioisotopes
often results in the identification and removal of* Correspondence: motomurak@hotmail.com
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reproduction in any medium, provided the ormultiple nodes as sentinel nodes, although most of these
nodes could be non-sentinel nodes because the dye
or radioisotope may migrate from sentinel nodes into
additional non-sentinel nodes. The excision and examin-
ation of multiple sentinel nodes reduces the false nega-
tive rate, but removal of a large number of sentinel
nodes increases morbidity and is time-consuming [6].
While some researchers have suggested that all dyed
and/or radioactive nodes should be removed [7,8], others
have proposed that the sentinel node biopsy procedure
should be stopped after some lymph nodes or all nodes
with radioactive counts greater than 10% of the hottest
node have been removed [9-14].
Recently, sentinel nodes have been reported to be well-
identified using computed tomography-lymphography
(CT-LG) in patients with breast cancer [15-19]. Lymphtral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Three-dimensional computed tomography-
lymphography (CT-LG) reconstructed from the first post-contrast
images. Contrast agent was injected intradermally into the skin
overlying the breast tumor and the subareolar skin. Lymphatic
vessels drained into a single axillary sentinel node (yellow arrow).
CT-LG can visualize lymph flow and can distinguish sentinel nodes
from non-sentinel nodes (white arrow).
Figure 2 Sentinel node (yellow arrow) identified by axial
computed tomography with localizing marker (white arrows).
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interstitial injection of CT contrast agent.
This study investigated whether CT-LG can distinguish
sentinel nodes from non-sentinel nodes by visualization of
the lymphatic channel and whether sentinel nodes identi-




One hundred and eighty-four consecutive patients with
clinical T1-2 breast cancers and clinically negative nodes
who underwent sentinel node biopsy at Osaka Medical
Center for Cancer and Cardiovascular Diseases between
February 2008 and December 2010 were enrolled in this
study. Patients with nonpalpable breast cancer, prior
axillary surgery or pregnancy were excluded. Patients
with a contraindication to CT or a known allergy to the
contrast agent were also excluded. The institutional re-
view board of Osaka Medical Center for Cancer and
Cardiovascular Diseases approved the study, and written
consent was obtained from all patients.
Sentinel node localization using CT-LG
Interstitial CT-LG was performed using a multidetector
row helical CT scanner (Light Speed VCT; GE Health-
care, Milwaukee, WI, USA). Contiguous 1.25-mm-thick
CT images from the upper thorax to axillary regions
were obtained once before administration of the contrast
agent. CT scanning with a detector of 0.625 mm, 64
rows was operated at 120 kV, 300 to 400 Auto-mA,
35 cm field of view, 512 x 512 matrix, section spacing of
1 mm, and table speed of 1.55 mm/0.5 sec.
Transaxial CT images were reconstructed with a 1.25-
mm pitch and slice thickness of 0.3 mm. 3D CT images
were reconstructed from the post-contrast CT images at
each time point with volume-rendering techniques and,
if necessary, a workstation (GE Advantage Workstation,
version 4.3; GE Healthcare) was used to further examine
lymph flow and sentinel nodes (Figure 1). Each patient
was placed in the supine position and their arms were
elevated. After local anesthesia with subcutaneous injec-
tion of 2 ml of 2% procaine hydrochloride, a 6-ml dose
of iopamidol (Iopamiron 370; Bayer Schering Pharma,
Osaka, Japan) was injected intradermally into the skin
overlying the breast tumors and into the subareolar skin.
A CT scan was performed after massaging the injection
site of iopamidol for one minute. A localizing marker,
which is usually used for CT-guided lung nodule biopsy,
was attached to the skin at the axilla to identify the sen-
tinel node location over the skin (Figure 2) [20]. Sentinel
nodes were identified as the first stained nodes on the
lymphatic flow from the injection sites of the contrast
agent.The sentinel node location was identified on the CT
image and was indicated precisely by the crossing point
of the localizing marker and the CT plane lights. The
site was marked on the skin surface using an oil pen
(Figure 3).
Surgery
Sentinel node biopsy was performed as described previ-
ously [21-23]. In brief, intradermal or intradermal and
Figure 3 The sentinel node was indicated precisely by the
crossing point of the localizing marker (white arrows) and the
computed tomography plane lights (black arrow). The site was
marked on the skin surface using an oil pen (yellow arrow).
Table 1 Patient characteristics






>2, ≤5 65 35.3
>5 5
Tumor location
Upper outer 101 54.9
Upper inner 35 19.0
Lower outer 26 14.1
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99 m tin colloid the day before surgery and peritumoral
or intradermal and subareolar injection of 5 mL indocy-
anine green (ICG, Diagnogreen 0.5%; Daiichi Pharma-
ceutical Co. Ltd., Nihonbashi, Tokyo, Japan) 10 minutes
before surgery were performed, and then the injection
site was massaged manually for one minute. Lymphos-
cintigraphy was performed 2–3 hours after the radioiso-
tope injection.
Breast surgery was performed before axillary surgery
in all patients to minimize the influence of radioactivity
from the injection site [21-23]. For surgery, the elevated
arm was placed as close as possible in the same position
as during CT marking. Hot nodes were identified using
a gamma probe (neo2000; Neoprobe Corporation,
Dublin, OH, USA). Dyed and/or hot nodes located just
under the markers using CT images were defined as sen-
tinel nodes and were removed first. All dyed nodes or all
nodes with an ex vivo radioisotope count of twofold or
greater than the axillary background were then removed.Invasive ductal 161 87.5
Invasive lobular 8 4.3











Sentinel nodes and dyed and/or hot nodes were serially
sectioned at 2 mm intervals. Hematoxylin and eosin sec-
tions of these nodes were prepared from each 2-mm
slice. An additional 4-μm section was cut and stained
with immunohistochemistry (IHC) using the avidin-
biotinylated peroxidase complex technique with the
mouse monoclonal antibody against cytokeratin (NCL-
CK19; Novocastra Laboratories Ltd., Newcastle, UK or
AE1/AE3; Thermoelectron Corp., Waltham, MA, USA).
Nodes with isolated tumor cells identified by IHC were
considered to be metastasis negative in this study, ac-
cording to the tumor node metastasis categories definedin the 6th edition of the Union Internacional Contra la
Cancrum TNM categories [24].
Statistical analysis
Fisher’s exact test and paired t-test was used for statis-
tical analysis. Differences were considered to be signifi-
cant when P <0.05.
Results
The mean age of the 184 patients was 55.7 (range, 31–
79) years old and the mean tumor size was 20.8 (range,
0.2-90) mm. Patient and tumor characteristics are sum-
marized in Table 1. The mean number of sentinel nodes
identified by CT-LG was significantly lower than that of
dyed and/or hot nodes removed (1.1 vs 1.8, p <0.0001).
One hundred sixty-one patients (87.5%) had 1 sentinel
node identified by CT-LG removed, 21 (11.4%) had 2
sentinel nodes removed, and 2 patients (1.1%) had 3
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had ≥2 sentinel nodes identified by CT-LG removed,
whereas 94 (51.1%) of patients had ≥2 dyed and/or hot
nodes removed (p <0.0001). Pathologic evaluation dem-
onstrated that 47 (25.5%) of 184 patients had metastasis
to at least one node. Three hundred twenty-eight dyed
and/or hot nodes were removed, of which 57 (17.4%)
had metastatic deposits. Two hundred eleven sentinel
nodes were removed, of which 52 (24.6%) had metastatic
deposits. Sixteen (30.8%) had micrometastases and 36
(69.2%) had macrometastases. All 47 patients demon-
strated metastases to at least one of the sentinel nodes
identified by CT-LG. No patient with negative sentinel
nodes had metastases in other dyed and/or hot nodes.
CT-LG could visualize lymph flow and accurately
identify sentinel nodes in 179 (97.3%) of 184 patients
(Figure 1). In 4 of the other 5 patients, only one sentinel
node was identified and it was not necessary to distin-
guish sentinel nodes from non-sentinel nodes by visual-
izing lymph flow. In one patient, two nodes were
identified and they could not be distinguished. No extra-
axillary sentinel nodes, such as internal mammary or
supraclaviculal sentinel nodes, were identified. Hot spots
could be identified over the skin using a gamma probe
on all markers of the sentinel node location by CT-LG.
There were no adverse events associated with CT-LG.
Discussion
Sentinel node biopsy using dye and radioisotopes often
results in the removal of multiple sentinel nodes. It re-
mains unclear how many and which lymph nodes must
be removed as sentinel nodes for accurate axillary sta-
ging. Removing only the first node identified or remov-
ing only the hottest node may not complete the sentinel
node biopsy. Wong et al. reported a false-negative rate
of 14.4% if only the first node had been taken [25].
Martin et al. demonstrated that the positive sentinel
node was not the most radioactive node in 20% of cases
with multiple sentinel nodes, and the false-negative rate
was likely to be much higher (12%) if only the most
radioactive sentinel node was removed [26]. Some re-
searchers recommend that all lymph nodes above a pre-
defined threshold of the ex vivo count of the hottest
sentinel node should be removed. The 10% rule is one of
the most common guidelines to define a radioactive sen-
tinel node and dictates removal of all sentinel node with
counts >10% of the most radioactive node. Martin et al.
demonstrated that the false-negative rate would be 13%
if only the hottest node was removed and 5.8% if the
10% rule was applied [13]. Sixty percent of patients had
>1 sentinel node removed and the mean number of sen-
tinel nodes per patient was 1.96. Chung et al. reported
that only 1.7% of all sentinel node-positive patients had
positive sentinel nodes with counts <10% radioactivecounts of the hottest node [14]. Sixty-five percent of pa-
tients had >1 sentinel node removed. More than one
sentinel node needs to be removed in many patients ac-
cording to the 10% rule. Others recommended that the
procedure can be stopped after a certain number of
lymph nodes have been removed. Zervos et al. found
98% of positive sentinel nodes were found in the first
three nodes removed [9]. McCarter et al. reported that
98% of positive sentinel nodes were found when the first
three nodes were removed [7]. Shrenk et al. found 99%
of positive sentinel nodes within the first two nodes and
100% of positive nodes within the first three nodes [8];
however, they both concluded that all dyed and/or hot
nodes should be removed to decrease the false-negative
rate. Chagper et al. found that only 89.7% of positive
sentinel nodes was identified within the first three nodes
and did not recommend removing only three sentinel
nodes because of a high false-negative rate of 10.3% [27].
Zakaria et al. demonstrated that 98% of patients with
positive nodes were found by the third sentinel node,
and 100% were found by the fourth sentinel node [10].
Yi et al. demonstrated that >99% of positive sentinel
nodes were identified in one of the first five lymph nodes
removed [11]. Woznick et al. reported that all positive
sentinel nodes were identified within the first six nodes
removed [12]. Removal of many more nodes was associ-
ated with a lower false-negative rate, but could worsen
the morbidity of the sentinel node biopsy. Wilke et al.
demonstrated an increased incidence of axillary seroma
and wound infection when more than four sentinel
nodes were removed [6].
In the present study, we demonstrated that sentinel
nodes could be successfully identified in 183 of 184 pa-
tients and metastases could be detected in all 47 patients
with positive nodes. CT-LG could visualize lymph flow
and accurately distinguished sentinel nodes from dyed
and/or hot non-sentinel nodes (Figure 1). Overall, 87.5%
of patients had only one sentinel node removed; 12.5% of
patients required removal of ≥2 sentinel nodes, whereas
51.1% of patients required removal of ≥2 dyed and/or
nodes, which was statistically significant (p <0.0001). In-
creased operative time, procedure and pathology cost, and
complication rate are associated with the removal of larger
numbers of sentinel nodes [6]. It is advantageous to re-
move only one lymph node as a sentinel node if these
nodes do not reduce mapping accuracy. Although four
CT studies were performed per patient in this study to
clarify which CT studies were really required, a single
post-contrast CT scan may be sufficient because the first
contrast CT image was able to identify lymphatic channels
and sentinel nodes accurately. A further study is required
to confirm the hypothesis. Another advantage of CT-LG is
that we can identify how many and which node should be
removed as sentinel nodes preoperatively. Moreover, we
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the depth from the skin, and in surrounding organs such
as the chest wall, muscle and vessels according to the
appearance of the axial CT and 3D-CT images (Figures 1
and 2). Some multiple sentinel nodes, which may be missed
when sentinel node biopsy is performed using dye and/or
radioisotopes without CT-LG because they are located far
from other nodes and influenced by radioactivity from the
injection site, could be accurately identified using CT-LG
(Figure 4). Furthermore, axial CT and 3D-CT images en-
abled the demonstration of the shapes and sizes of sentinel
nodes (Figures 1 and 4). The use of 3D images is useful for
identification and removal during sentinel node biopsy.
On the other hand, our study had a few limitations,
including that the false negative rate of this procedure
for axillary staging could not be shown because axillary
lymph node dissection was not performed. Sentinel node
biopsy has now become the standard of care and it is
impracticable to perform axillary lymph node dissection
after sentinel node biopsy for sentinel node-negative pa-
tients, even in the trial setting. However, all 47 patients
with positively dyed and/or hot nodes demonstrated me-
tastases to at least one of the sentinel nodes identified
by CT-LG and no patient with negative sentinel nodes
had metastases in other dyed and/or hot nodes; there-
fore, the diagnostic accuracy of sentinel nodes for axil-
lary staging is similar to that of sentinel nodes identified
by dye and radioisotopes, demonstrated in our previousFigure 4 Three sentinel nodes were identified by computed
tomography -lymphography (CT-LG). One (yellow arrow) might
have been missed when sentinel node biopsy was performed
without CT-LG because it was located far from the other two nodes
(white arrows) and was influenced by radioactivity from the
injection site.study with 100% sensitivity, 100% specificity, and 100%
accuracy [21]. Intradermal injection of enhanced agents
cannot identify extra-axillary sentinel nodes, but removal
of sentinel nodes in such a region has not been performed
recently. Chagper et al. demonstrated that axillary sentinel
nodes are usually identified even when lymphoscintigraphy
shows drainage to the internal mammary nodes alone [28].
Lymphoscintigraphy can sometimes show several hot
nodes and lymphatic flow before sentinel node biopsy
[29]; however, it is not easy to clearly distinguish sentinel
nodes from non-sentinel nodes in many cases because of
unclear lymph flow images and only identification of the
hottest node in spite of the existence of more than one
hot node. CT-LG can identify sentinel nodes clearly.
Moreover, if sentinel nodes accurately be diagnosed using
imaging, even sentinel node biopsy can be omitted. CT
itself is reported to be insufficient to evaluate the presence
of metastases in sentinel nodes [30]. We recently tried to
perform MR imaging with superparamagnetic iron oxide
enhancement for the accurate detection of metastases in
sentinel nodes localized by CT-LG in patients with breast
cancer [31]. The sensitivity, specificity, and accuracy of
MR imaging for the diagnosis of sentinel node metastases
were 84.0%, 90.9%, and 89.2%, respectively. In 4 of 10 pa-
tients with micrometastases, metastases were not detected,
but all 15 patients with macrometastases were successfully
identified. This promising procedure may avoid even
sentinel node biopsy when the sentinel node is diagnosed
as disease-free on MR imaging.Conclusions
CT-LG could distinguish sentinel nodes from non-
sentinel nodes, and sentinel nodes accurately staged the
axilla in patients with breast cancer. Applying this pro-
cedure may end the dispute regarding how many and
which axillary lymph nodes need to be removed as senti-
nel nodes for accurate axillary staging. Successful identi-
fication of sentinel nodes using CT-LG may facilitate
image-based diagnosis of metastasis, possibly leading to
the omission of sentinel node biopsy.Abbreviations
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